CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the appointment of Lee Kalowski as chief financial officer, effective immediately. Mr. Kalowski brings more than a decade of experience in the life sciences sector to Tokai.
“We are delighted to welcome Lee to Tokai’s management team. Lee brings finance, strategy and industry expertise to Tokai as well as a deep knowledge of the prostate cancer therapeutics market,” stated Jodie Morrison, president and chief executive officer. “Overseeing financial operations at Tokai, we expect Lee will be instrumental to the team as we work to bring our lead product candidate, galeterone, into Phase 3 development and advance our Androgen Receptor Degrading Agents (ARDA) platform.”
Help employers find you! Check out all the jobs and post your resume.
